Hematocrit on TRT: The Number Your App Should Be Watching

What is hematocrit?

Hematocrit (HCT) is the percentage of your blood volume occupied by red blood cells. Normal range for men: 38.3–48.6%. It is a simple number on your CBC (complete blood count), but it carries outsized importance for anyone on testosterone replacement therapy.

Higher hematocrit means thicker blood — more oxygen-carrying capacity, but also more viscosity. The tradeoff is real. Within the normal range, a higher hematocrit improves endurance and recovery. Beyond it, you are increasing resistance in every vessel in your body. Too high, and you are rolling the dice on clots, stroke, or cardiovascular events.

Most fitness apps do not track hematocrit. Most do not even know the term exists. If you are on TRT, this is arguably the single most important lab value that no consumer health tool is watching for you.

Why TRT raises it.

Testosterone stimulates erythropoiesis — the production of red blood cells. It does this through two primary mechanisms: increasing erythropoietin (EPO), the hormone that signals your bone marrow to produce more red blood cells, and suppressing hepcidin, a hormone that regulates iron availability for hemoglobin synthesis.^[1]

Bachman et al. (2014) demonstrated that testosterone significantly stimulates red blood cell production, with hematocrit commonly rising 3–8 percentage points on TRT — though individual responses vary widely depending on dose, delivery method, and baseline levels.^[1] This is not a rare side effect. It is the most common lab abnormality in men on TRT, and it is dose-dependent — higher testosterone levels generally mean higher hematocrit.

The response is also influenced by delivery method. Injectable testosterone (particularly longer esters like cypionate and enanthate) tends to produce larger hematocrit elevations than transdermal gels or patches, likely because injections create supraphysiological peaks that drive stronger erythropoietic signaling before troughing. More frequent, smaller injections can attenuate this effect by reducing peak-to-trough variation.

The numbers: when to pay attention.

Not all elevations are equal. The Endocrine Society provides general thresholds for clinical decision-making, though your physician may adjust these based on your individual history and risk factors.^[3]

These thresholds are general guidelines. Your doctor may use slightly different cutoffs based on your cardiovascular history, altitude, smoking status, and other risk factors. The key principle: trending matters more than any single reading. A hematocrit of 51% that was 47% three months ago tells a different story than a stable 51% that has held for a year.

Erythrocytosis vs. polycythemia.

An important distinction that is frequently conflated. TRT-induced erythrocytosis is a secondary response to exogenous testosterone — your body is doing what it is supposed to do when testosterone is present. The bone marrow receives a signal. It produces more red blood cells. The mechanism is predictable and well-understood.

Polycythemia vera is a fundamentally different condition. It is a primary bone marrow disorder — a myeloproliferative neoplasm caused by a mutation (usually JAK2 V617F) that causes uncontrolled red blood cell production independent of EPO signaling. It is, in clinical terms, a cancer.

They present similarly on a CBC. Both show elevated hematocrit and hemoglobin. But their causes, trajectories, and treatment approaches are entirely different. If your hematocrit is elevated on TRT, the appropriate response is monitoring and dose management — not panic. Your physician can distinguish between the two with additional labs (EPO level, JAK2 mutation testing) if there is any clinical suspicion.

What to do when it climbs.

When hematocrit trends upward, the response should be proportional and systematic. These interventions are listed roughly in order of clinical priority:

• •Hydration. Dehydration artificially elevates hematocrit by reducing plasma volume. Drink 2.5–3L of water daily, especially in the 24 hours before a lab draw. A "high" reading taken while dehydrated may normalize with adequate fluid intake alone.
• •Dose adjustment. Lowering the TRT dose is the most direct intervention. Even modest reductions — 200mg to 160mg per week, for example — can meaningfully lower HCT while maintaining therapeutic testosterone levels. Work with your prescriber to find the minimum effective dose.
• •Injection frequency. More frequent, smaller doses (e.g., every 3.5 days instead of weekly) produce more stable serum levels and may reduce hematocrit spikes by avoiding the supraphysiological peaks that drive erythropoiesis hardest.
• •Therapeutic phlebotomy. Donating blood or having blood drawn therapeutically reduces red blood cell volume directly. It is effective but temporary — the effect lasts 4–8 weeks before the bone marrow compensates. It is a management tool, not a solution.

The goal is not to eliminate the erythropoietic response entirely. Some degree of hematocrit elevation on TRT is expected, normal, and even beneficial for oxygen delivery. The goal is to keep it within a range where the cardiovascular risk remains acceptably low.

Lab monitoring schedule.

The Endocrine Society recommends the following monitoring cadence for men on TRT.^[3] These are minimums — your physician may increase frequency based on your response.

Beyond CBC and hematocrit, your monitoring panel on TRT should also include: PSA (prostate-specific antigen), lipid panel, testosterone levels (total and free), and estradiol. These are not optional extras. They are the minimum dataset for responsible hormone management.

The TRAVERSE trial context.

The TRAVERSE trial (Bhasin et al., 2023) was the largest cardiovascular safety trial for TRT ever conducted — 5,246 men with established cardiovascular disease or elevated cardiovascular risk, followed for a mean of 33 months.^[2]

The primary finding: TRT did not increase the risk of major adverse cardiovascular events (MACE) compared to placebo. The hazard ratio was 0.96 (95% CI, 0.78–1.17). This was a landmark result because it addressed decades of conflicting observational data and two earlier trials that had raised safety concerns about TRT and cardiovascular risk.

However — and this is the critical nuance — participants with baseline hematocrit above 48% were excluded from enrollment, and those whose hematocrit exceeded 54% during the trial had mandatory dose adjustments. The safety finding assumes proper monitoring. The trial did not prove that unmonitored TRT is safe. It proved that monitored TRT, with hematocrit management, does not increase cardiovascular events.

The takeaway is clear and important: the risk is not the testosterone. It is the unmonitored testosterone. TRT appears cardiovascularly safe when hematocrit is tracked, thresholds are respected, and dose adjustments are made when the numbers warrant them. The men in TRAVERSE who did well were the men whose labs were watched.

References.